Long-Term Efficacy and Potential Predictors of Tralokinumab Dose Optimization in Elderly Patients: A Multicentre Study
Tralokinumab demonstrated sustained efficacy and safety in elderly patients with moderate-to-severe AD, even with multiple comorbidities. Dose optimization to Q4 W was feasible in a subset of patients. Early systemic treatment initiation was linked to better outcomes, emphasizing the need for proactive disease management.
Authors
- Pedro Mercader (ORCID: https://orcid.org/0000-0002-8309-9725)
- Sergio Santos‐Alarcón (ORCID: https://orcid.org/0000-0002-0533-1605)
- Francisco Javier Melgosa Ramos (ORCID: https://orcid.org/0000-0003-2121-6727)
- J.M. Sánchez Motilla
Institutions
- Hospital General Universitario Morales Meseguer (ES)
- Hospital Universitario Doctor Peset (ES)
- Hospital Universitario Lluís Alcanyís (ES)
- Hospital Virgen de los Lirios (ES)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1007/s13555-025-01405-2
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59